including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
The annual global premier event in nuclear medicine and molecular imaging, the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has officially kicked off.
View moreNiowave, Inc. and Ratio Therapeutics Sign Supply Agreement for Actinium-225 to Advance Targeted Alpha Therapies
IBA launches Cyclone® iKure, a cyclotron designed for industrial scale Astatine-211 production
Curium Announces a Strategic Investment of Over €32 million in Saclay, France
ASCO: Lu-177 edotreotide yields sustained quality-of-life gains
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
